Get started
Author

TaeHong Park

Observed names: Park, TaeHong, Tae Hong Park, Taehong Park
Observed institution: Celltrion (South Korea)
ORCID: 0000-0003-1922-2810
Observed ORCID: 0000-0003-1922-2810
OpenAlex ID: A5090770578
A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males
2019 · Sang-Heon Cho, Seunghoon Han, et al. · BioDrugs · 23
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
2022 · Claire Verschraegen, Zoran Andric, et al. · BioDrugs · 13
PDF
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
2023 · Justin Stebbing, Yauheni Baranau, et al. · BioDrugs · 6
PDF
A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea
2023 · Jae-Cheol Jo, Youngwoo Jeon, et al. · Expert Opinion on Biological Therapy · 3
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study
2024 · Min Ho Park, Jae Hong Seo, et al. · Expert Opinion on Biological Therapy · 2
PDF
Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea
2022 · Seok-Goo Cho, Jae-Cheol Jo, et al. · Blood · 2
Abstract CT551: Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin®) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)
2022 · Yuichiro Ohe, Igor Bondarenko, et al. · Cancer Research · 1
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer
2026 · Taekyung Kim, Heungjo Kim, et al. · BioDrugs
PDF
Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer
2025 · Zoran Andric, Fedor Moiseenko, et al. · Cancer Treatment and Research Communications
Works count: 10
Citation count: 50
H-index: 3
I10-index: 2
Year
Topic
Type